HDAC/σ1R Dual-Ligand as a Targeted Melanoma Therapeutic
<b>Background:</b> In melanoma, multiligand drug strategies to disrupt cancer-associated epigenetic alterations and angiogenesis are particularly promising. Here, a novel dual-ligand with a single shared pharmacophore capable of simultaneously targeting histone deacetylases (HDACs) and sigma recepto...
Uloženo v:
| Hlavní autoři: | , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI AG
2025-01-01
|
| Edice: | Pharmaceuticals |
| Témata: | |
| On-line přístup: | https://www.mdpi.com/1424-8247/18/2/179 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
